retatrutide triple agonist glp-1 gip glucagon phase 2 obesity G Agonists – Retatrutide. What is all the buzz? – Dr Girouard's Retatrutide (40mg) - theragenetics

According to Global Market Insights, the market size for GLP-1 drugs is expected to increase from $22.4 billion in 2022 to $55.8 billion in 2032

Drug Target Complex Belonging to the class B G-protein-coupled receptor, GLP-1R is a seven-transmembrane protein receptor (Figure 2)

So, before starting or stopping GLP-1 medications whether for weight loss or diabetes its important for people to check in with a health care provider

Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes

Lund, A., Knop, F

Adding external GLP-1either through IV at high doses or as medicationslows down stomach emptying quite a bit